If you or someone you love has been noticing memory slips, difficulty finding words, or trouble keeping up with complex tasks — but is otherwise managing daily life reasonably well — you may have heard the term Mild Cognitive Impairment, or MCI. MCI sits in a critical space between the normal cognitive changes of aging and the more significant impairment that characterizes dementia. It is more than forgetfulness, but less than a diagnosis of Alzheimer’s disease or another dementia.

Recent research involving nearly 288,000 older adults found that approximately 23.7% of the global geriatric population meets criteria for MCI PubMed Central — making it one of the most common conditions affecting older adults today, and one of the most important to identify early.

MCI Is Not a Sentence — But It Deserves Attention

One of the most reassuring and important things to understand about MCI is that it does not inevitably lead to dementia. A 2025 systematic review and meta-analysis found that the pooled prevalence of reversion from MCI to normal cognition was approximately 31% ScienceDirect — meaning that roughly one in three people diagnosed with MCI may return to normal cognitive functioning. At the same time, MCI does carry meaningful risk. Conversion rates to dementia vary widely across studies, and reversion to normal cognition has gained increasing research attention as scientists work to better understand what determines which path a person takes. Wiley Online Library

A 2025 study published in BMC Medicine followed nearly 800 older adults over six years and found that reversion from MCI to normal cognition was associated with an 89.6% lower risk of Alzheimer’s disease dementia compared to those who remained stable with MCI. BioMed Central This finding underscores a critical point: the trajectory of MCI is not fixed, and early, accurate identification gives patients and their care teams the best opportunity to intervene.

Why a Brief Screening Test Is Not Enough

Many people receive a brief cognitive screening — such as the Montreal Cognitive Assessment (MoCA) or the Mini-Mental State Examination (MMSE) — during a routine medical appointment. While these tools serve an important role in flagging potential concerns, they were designed as screening instruments, not diagnostic ones. They are not built to characterize the full range of cognitive abilities, identify the specific pattern of a person’s strengths and weaknesses, or determine what is driving the cognitive changes.

A 2025 review published in Frontiers in Psychology made this point directly: the prognosis of MCI is often uncertain, partly due to variable etiologies and partly due to commonly employed brief and incomplete cognitive assessments. More comprehensive neuropsychological assessment based on age- and education-corrected norms has shown superior validity regarding neuropathology and prognosis and is recommended as best practice. Frontiers

The same review noted that brief screening tools may not capture a person’s premorbid — or pre-illness — level of functioning, which is essential context for interpreting whether a current score actually represents a meaningful decline. A person who was highly educated and cognitively sharp throughout their career may score in the “normal” range on a brief screening while actually having declined significantly from their personal baseline.

The 2025 Alzheimer’s Association Clinical Practice Guidelines recommend neuropsychological evaluation as a critical component of any thorough diagnostic workup for suspected MCI or dementia — particularly when brief office-based screening is not sufficiently informative, or when a patient’s results don’t match their reported symptoms.

What a Comprehensive Neuropsychological Evaluation Provides

A comprehensive neuropsychological evaluation goes far beyond what any brief screening can offer. It assesses multiple cognitive domains — including memory, attention, processing speed, language, visuospatial abilities, and executive functioning — using standardized tests with validated norms adjusted for age, education, and cultural background. The result is a detailed cognitive profile unique to that individual.

A 2025 paper published in Alzheimer’s & Dementia, written in support of the Alzheimer’s Association’s new clinical practice guidelines, described the role of neuropsychological assessment as providing a basis for early and accurate diagnosis and staging, characterizing the clinical profile, assessing cognitive trajectory over time, and providing recommendations specifically tailored to the individual and their care team. PubMed Central

For someone with MCI, this level of detail matters enormously. It can help determine:

Whether the pattern of cognitive change is consistent with a neurodegenerative process like Alzheimer’s disease, or more consistent with a treatable condition such as depression, sleep apnea, thyroid dysfunction, or vitamin deficiency
Which specific cognitive domains are affected and which remain intact
How a person’s current functioning compares to what would be expected given their age, education, and background
What recommendations for treatment, lifestyle modification, or further workup are most appropriate

The Role of Neuropsychological Criteria in Predicting Outcomes

Research published in 2025 in Scientific Reports followed more than 1,000 older adults without dementia over 12 years, comparing conventional MCI diagnostic approaches with more comprehensive neuropsychological criteria. Both classification methods were associated with a comparable risk of dementia over time, reinforcing the importance of early and informative diagnosis for planning timely and appropriate interventions aimed at dementia risk reduction. Nature

What this means for patients is that a thorough evaluation — conducted early — provides a meaningful and scientifically grounded foundation for understanding risk and taking action.

Catching What Can Be Treated

Not all cognitive decline is neurodegenerative. Some of the most important contributions a neuropsychological evaluation can make are in identifying conditions that mimic MCI but are treatable. Hypothyroidism, B12 deficiency, depression, anxiety, medication side effects, sleep disorders, and vascular risk factors can all produce cognitive symptoms that look like early dementia on a brief screening. A comprehensive evaluation — combined with a thorough medical workup including laboratory testing and neuroimaging — helps ensure that treatable causes are identified and addressed before assuming a neurodegenerative etiology.

A Note on New Disease-Modifying Treatments

The landscape of Alzheimer’s disease treatment is changing. New disease-modifying therapies are now available or in late-stage development for individuals in the early stages of Alzheimer’s disease, including those at the MCI stage. These treatments require early and accurate identification of the right candidates. A comprehensive neuropsychological evaluation is a critical component of that identification process, providing objective data about cognitive status that complements biomarker and imaging findings.

When Should You Consider an Evaluation?

Consider requesting a neuropsychological evaluation if you or someone you care for is experiencing:

Memory changes that seem beyond normal aging — particularly difficulty learning and retaining new information
Increasing difficulty with complex tasks such as managing finances, following multi-step directions, or navigating familiar routes
Word-finding difficulties that are new or worsening
Concerns raised by a family member or physician about cognitive changes
A desire for a clear, objective baseline to track cognitive health over time

Early evaluation provides the clearest picture of what is happening — and the most opportunity to act on it.

Advanced Neuropsychology and Psychology Services, PLLC provides comprehensive neuropsychological evaluations for individuals with concerns about MCI and other cognitive concerns. To learn more or request an appointment, please visit us at https://www.advnps.com or call (623) 246-1256.